Candel Therapeutics has been upgraded from Buy to Strong Buy following successful phase 3 trial results for its prostate cancer treatment, aglatimagene. The trial showed a 30% reduction in disease recurrence risk, supporting a planned Biologics License Application (BLA) filing in late 2026. The company is also progressing with trials in metastatic lung cancer and is financially secure through early 2028, with a significant market opportunity in prostate cancer treatment.
Candel Therapeutics' recent upgrade to Strong Buy is noted here with Pluang's health sector data for context. Of 100 priced health-sector US stocks on Pluang, 75 rose and 25 fell today. As of Sep 23, 2026 00:42 WIB, ClearPoint Neuro Inc (CLPT) traded at USD 14.74 with a 5.51% increase, while Novavax Inc (NVAX) was at USD 10.93, down 5.00% in sell-heavy activity, and Aurora Cannabis Inc (ACB) rose 4.71% to USD 4.22 with full buy orders.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
Apple's new CEO, John Ternus, is under pressure from Washington to abandon a Chinese memory chip deal that former CEO Tim Cook fought to maintain. This comes as Apple faces rising memory costs, which have significantly impacted iPhone pricing and pro...
Domino's abruptly closed 13 franchise-operated stores in Ohio, managed by Anthony Satterwhite, due to financial struggles. Employees were informed via text message during a busy dinner shift, causing immediate job losses and customer order disruption...
NEAR has teamed up with Ondo Finance to allow eligible users to buy 20 tokenized U.S. stocks, ETFs, and commodity-linked products using crypto assets like Bitcoin and USDC on near.com and NEAR Intents. This integration enables purchases without needi...
Kroger announced its AI strategy at GroceryShop 2026, focusing on improving customer experience, easing associate work, and driving better business outcomes. The company leverages extensive customer data and proprietary AI models for demand forecasti...
